Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
DTIL Insider Transactions (Form 4)
73
35 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 1 of 2.
PRECISION BIOSCIENCES INC (DTIL) had 9 insider filings in the last 90 days, with the most recent on 2026-06-05. The full record for DTIL runs to 35 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying DTIL stock?
No insider purchases of DTIL were filed in the last 90 days. 6 purchases are on record for this company.
How many insiders are selling DTIL stock?
No insider sales of DTIL were filed in the last 90 days. 14 sales are on record for this company.
Where can I see DTIL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks DTIL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow DTIL insider buys?
Create a free InsiderAlpha account and press Watch on this page to add DTIL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Melinda Brown - Director
